ConvaTec Group (LSE:CTEC) is working through a $200m share buyback announced with its interim results on 4 August 2026, alongside a 15% increase in its interim dividend. The medical products maker reaffirmed its 2026 guidance and has issued no major company-specific news since.

What happened

ConvaTec reported first-half revenue of $1,232m, up 4.4% year on year. Organic growth was 5.0% excluding InnovaMatrix, its wound biologics product.

Adjusted operating profit rose 3.9% to $262m, despite a $69m non-cash impairment linked to changes in US reimbursement for InnovaMatrix. Adjusted diluted earnings per share increased 6.3%.

The company raised its interim dividend by 15% and launched a $200m share buyback, which it intends to complete by the end of the year.

Drivers of growth

Growth was described as broad-based across its chronic care categories. New product launches including ConvaFoam, Esteem Body and GentleCath Air contributed, along with solid demand in infusion care for diabetes and Parkinson's disease therapies.

The InnovaMatrix impairment reflects how changes in US reimbursement rules can affect the value of individual products, even when the wider business is growing. Excluding that product, organic growth was ahead of the reported revenue increase.

Why it matters for investors

ConvaTec Group is a constituent of the FTSE All-Share index in the Medical Equipment and Services sector. It makes products for chronic conditions, including ostomy care, continence care, wound care and infusion devices, markets that tend to be less sensitive to the economic cycle.

ConvaTec reaffirmed its 2026 guidance of mid-single-digit organic revenue growth, an operating margin of at least 23%, double-digit earnings per share growth and cash conversion of around 100%.

Under its medium-term "Accelerate" plan, the company targets operating margins in the mid-20s and sustainable annual revenue growth of 6% to 8% from 2027. ConvaTec backed its full-year outlook and pointed to a firmer second half.

How the shares have performed

The company's market value was around £4.37bn.

The combination of buyback and dividend growth means ConvaTec is returning more cash to shareholders while still investing in new products, supported by its target of near-full cash conversion.

The interim results also showed the trade-off investors are weighing. Underlying demand across chronic care looks steady, but regulatory decisions in the US can still produce sizeable one-off charges, as the $69m InnovaMatrix impairment demonstrated. How management manages that exposure will influence how the market values the group's growth ambitions over the next few years.

What to watch next

The second half will be important for ConvaTec to meet double-digit earnings per share growth, given the more modest 6.3% rise in the first half. Management has pointed to firmer growth in the second half.

Investors will watch progress on the $200m buyback and any further news on US reimbursement for wound biologics. A trading update or full-year results early in 2027 will show whether the company met its margin target of at least 23%.

Progress towards the 6% to 8% revenue growth target from 2027 will also be a central theme, as investors assess whether recent product launches can lift the group's growth rate.